Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04046939 · ClinicalTrials.gov registry record · Phase 2

Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma

A Phase 2 study of Asthma and Eosinophilic Asthma, sponsored by Knopp Biosciences.

Completed
Registry status
Phase 2
Development phase
534
Enrollment target
20
Study locations

NCT04046939 is a Phase 2 study of Asthma and Eosinophilic Asthma that has completed, run by Knopp Biosciences. The registered enrollment target is 534 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04046939, a Phase 2 study of Asthma and Eosinophilic Asthma, has completed, sponsored by Knopp Biosciences.

COMPLETED
Registry status
Phase 2
Development phase
534 participants
Enrollment target
20
Study locations

Study Summary

This is a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging, multi-center study to evaluate the clinical effects of oral administration of dexpramipexole for 12 weeks on peripheral blood eosinophil count in subjects with eosinophilic asthma.

Conditions Studied

Asthma Eosinophilic Asthma

Interventions

  • DRUG Placebo
  • DRUG Dexpramipexole

Study Locations (20)

Florida

  • Research Site - Daytona Beach
  • Research Site - Miami
  • Research Site - Orlando
  • Research Site - Tampa
  • Research Site - Tampa

California

  • Research Site - Los Angeles
  • Research Site - Mission Viejo
  • Research Site - Westminster

Georgia

  • Research Site - Lawrenceville
  • Research Site - Winder

Missouri

  • Research Site - St Louis
  • Research Site - St Louis

New York

  • Research Site - Corning
  • Research Site - New Hyde Park

Colorado

  • Research Site - Denver

Idaho

  • Research Site - Boise

Michigan

  • Research Site - Farmington Hills

Trial Details

FieldValue
Enrollment Target 534 participants
Start Date 2019-08-15
Est. Completion 2021-03-02
Phase Phase 2

Sponsor

Knopp Biosciences

12 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04046939

The ClinicalTrials.gov registry entry for NCT04046939 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 534 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (66% lower). The listed sponsor is Knopp Biosciences, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04046939 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Georgia.

Frequently Asked Questions

What is clinical trial NCT04046939 about?

NCT04046939 is a clinical study titled "Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma". This is a randomized, double-blind, placebo-controlled, parallel-group, dose-ranging, multi-center study to evaluate the clinical effects of oral administration of dexpramipexole for 12 weeks on peripheral blood eosinophil count in subjects with eosinophilic asthma.

What is the current status of trial NCT04046939?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 534 participants. The study started on 2019-08-15. Estimated completion is 2021-03-02.

What conditions does trial NCT04046939 study?

This clinical trial studies the following conditions: Asthma, Eosinophilic Asthma.

What interventions are being tested in trial NCT04046939?

The interventions under investigation include: Placebo (DRUG), Dexpramipexole (DRUG).

Who is sponsoring clinical trial NCT04046939?

This trial is sponsored by Knopp Biosciences, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04046939 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Georgia, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Asthma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Asthma

All registered trials for this condition

Eosinophilic Asthma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.